Core Viewpoint - Nanjing Pharmaceutical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report disclosure laws, leading to the termination of its major asset restructuring plan [2][4]. Group 1: Regulatory Actions - The CSRC issued a notice of investigation to Nanjing Pharmaceutical due to alleged violations of the Securities Law and the Administrative Penalty Law of the People's Republic of China [2]. - The company announced the termination of its major asset restructuring plan, which was initially intended to involve a cash acquisition without issuing shares or changing control [4]. Group 2: Financial Performance - Since its listing in 2020, Nanjing Pharmaceutical has experienced a continuous decline in revenue and has been in a state of loss since 2021, with a significant loss of 357 million yuan in 2024 [4]. - In the first half of 2025, the company reported revenue of 61.8463 million yuan, a year-on-year decrease of 71.28%, with a net profit of -40.0023 million yuan and a non-recurring net profit of -41.7314 million yuan [4]. Group 3: Market Position - Nanjing Pharmaceutical focuses on the research, production, and sales of antiviral drugs for influenza and other infectious diseases, as well as treatments for major diseases such as malignant tumors, cardiovascular diseases, and diabetes [4]. - As of September 30, 2025, the company's stock price closed at 11.37 yuan per share, with a market capitalization of 3.12 billion yuan [6].